Chicago – September 02, 2026
President Donald Trumpâs administration has reached agreements with nine major pharmaceutical companies aimed at lowering the cost of prescription medicines for Medicaid beneficiaries.
The deals are part of the administrationâs broader effort to reduce government spending on prescription drugs and expand access to lower-cost medications. Participating drugmakers are expected to provide price concessions or other savings on selected medicines supplied through Medicaid.
The agreements come as Washington faces growing pressure over high prescription-drug prices and healthcare costs. The Trump administration has made drug pricing a major policy priority, arguing that Americans pay more for many medicines than patients in other countries.
The companies involved span major areas of the pharmaceutical industry, including treatments for chronic and serious illnesses.
Officials say the agreements could generate significant savings for taxpayers and Medicaid, while potentially reducing costs for millions of low-income Americans who rely on the program for healthcare.
